Adjuvant systemic treatment for individual patients with triple negative breast cancer

Carey, 2007, The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes, Clin Cancer Res, 13, 2329, 10.1158/1078-0432.CCR-06-1109 Haffty, 2006, Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer, J Clin Oncol, 24, 5652, 10.1200/JCO.2006.06.5664 Huober, 2010, Prognosis of medullary breast cancer: Analyses of 13 International Breast Cancer Study Group (IBCSG) trials, J Clin Oncol, 28, 15s, 10.1200/jco.2010.28.15_suppl.630 Weigelt, 2010, The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade, J Pathol, 220, 263, 10.1002/path.2648 Bertucci, 2008, How basal are triple-negative breast cancers?, IntJ Cancer, 123, 236, 10.1002/ijc.23518 Kandel, 2006, Prevalence of BRCA-1 mutations in triple negative breast cancer (BC)J, Clin Oncol, 24, 18s Turner, 2004, Hallmarks of ‘BRCAness’ in sporadic cancers, Nat Rev Cancer, 4, 814, 10.1038/nrc1457 Le Tourneau, 2007, 47% pathologic complete response rate to anthracyclines-based associated with high cyclophosphamide doses neoadjuvant chemotherapy in basal-like and triple negative breast cancer patients, Breast Cancer Res Treat, 106, 1s Keam, 2007, Prognostic impact of clinicopathologic parameters in stage 11/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer, BMC Cancer, 7, 203, 10.1186/1471-2407-7-203 Bidard, 2008, p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes, Ann Oncol, 19, 1261, 10.1093/annonc/mdn039 Liedtke, 2008, Response to neoadjuvant therapy and long-term survival in patients with triple negative breast cancer, J Clin Oncol, 26, 1275, 10.1200/JCO.2007.14.4147 Wang, 2009, Response to neoadjuvant therapy and disease free survival in patients with triple-negative breast cancer, Can To Kagaku Ryoho, 36, 255 Fernandez-Morales, 2006, Analysis of the pathological response to primary chemotherapy in patients with locally advanced breast cancer (LABC) grouped according to ER, PR and HER2 status, J Clin Oncol, 24, 18s, 10.1200/jco.2006.24.18_suppl.626 Huober, 2010, Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study, Breast Cancer Res Treat, 124, 133, 10.1007/s10549-010-1103-9 Straver, 2010, The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer, Breast Cancer Res Treat, 119, 551, 10.1007/s10549-009-0333-1 Esserman, 2009, Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657), J Clin Oncol, 27, 18s, 10.1200/jco.2009.27.18_suppl.lba515 Parker, 2009, Breast cancer molecular subtypes predict response to anthracycline/taxane-based chemotherapy, Cancer Res, 69, 24s, 10.1158/0008-5472.SABCS-09-2019 Rouzier, 2005, Breast cancer molecular subtypes respond differently to preoperative chemotherapy, Clin Cancer Res, 11, 5678, 10.1158/1078-0432.CCR-04-2421 Berry, 2006, Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer, JAMA, 295, 1658, 10.1001/jama.295.14.1658 Gennari, 2008, HER-2 status and efficacy of adjuvant anthracyclines in early breast cancer: A pooled analysis of randomized trials. J, Natl Cancer Inst, 100, 14, 10.1093/jnci/djm252 Hugh, 2009, Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial, J Clin Oncol, 27, 1168, 10.1200/JCO.2008.18.1024 Ellis, 2009, Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial, lancet, 373, 1681, 10.1016/S0140-6736(09)60740-6 Berry, 2009, Benefits of adding paclitaxel to adjuvant doxorubicin/cyclophosphamide depending on HER2 & ER status: analysis of tumor tissue microarrays and immunohistochemistry in CALGB 9344 (Intergroup 0148), Cancer Res, 69, 24s, 10.1158/0008-5472.SABCS-09-606 Di Leo, 2010, Overall survival benefit for sequential doxorubicin-docetaxel compared to concomitant doxorubicin and docetaxel in node-positive breast cancer. 8-yr. Results of the Breast International Group (BIG) 2-98 Phase III Adjuvant Trial, Cancer Res, 69, 24s Early Breast Cancer Trialists' Collaborative Group (EBCTCG), 2005, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials, Lancet, 365, 1687, 10.1016/S0140-6736(05)66544-0 Treszezamsky, 2007, BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II, Cancer Res, 67, 7078, 10.1158/0008-5472.CAN-07-0601 Quinn, 2003, BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis, Cancer Res, 63, 6221 Tassone, 2003, BRCA1 expression modulates chemosensitivity of BRCAl-defective HCC1937 human breast cancer cells, Br J Cancer, 88, 1285, 10.1038/sj.bjc.6600859 Petit, 2007, Are BRCA1 mutations a predictive factor for anthracycline-based neoadjuvant chemotherapy response in triple-negative breast cancers?, Clin Oncol, 25, 18s Delaloge S, Pautier R Kloos I, et al. BRCAl-linked breast cancer (BC) is highly more chemosensitive than its BRCA2-linked or sporadic counterparts. Paper presented at 27th Congress of the European Society for Medical Oncology; October 18-22, 2002; Nice, France (abstract 120). Chappuis, 2002, A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J, Med Genet, 39, 608, 10.1136/jmg.39.8.608 Dhesy-Thind, 2008, Her-2/neu in systemic therapy for women with breast cancer: a systemic review, Breast Cancer Res Treat, 109, 209, 10.1007/s10549-007-9656-y Di Leo, 2010, Final results of a meta-analysis testing HER2 and topoisomerase Ha genes as predictors of incremental benefit from anthracyclines in breast cancer, J Clin Oncol, 28, 15s, 10.1200/jco.2010.28.15_suppl.519 Cheang, 2009, Anthracyclines in basal breast cancer: The NCIC-CTG trial MA5 comparing adjuvant CMF to CEFJ, Clin Oncol, 27, 15s Rottenberg, 200717, Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer, Proc Natl Acad Sci, 104, 12117, 10.1073/pnas.0702955104 Leong, 2007, The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers, J Clin Invest, 117, 1370, 10.1172/JCI30866 Byrski, 2009, Response to neo-adjuvant chemotherapy in women with BRCAl-positive breast cancers, Breast Cancer Res Treat, 115, 359, 10.1007/s10549-008-0128-9 Gronwald, 2009, Neoadjuvant therapy with cisplatin in BRCAl-positive breast cancer patients, J Clin Oncol, 27, 15s, 10.1200/jco.2009.27.15_suppl.502 Byrski, 2010, Pathologic complete response rates in young women with BRCAl-positive breast cancers after neoadjuvant chemotherapy.;, Clin Oncol, 28, 375, 10.1200/JCO.2008.20.7019 Silver, 2010, Efficacy of neoadjuvant cisplatin in triple-negative breast cancer, J Clin Oncol, 28, 1145, 10.1200/JCO.2009.22.4725 Bhattacharyya, 2009, Single institution phase II study of weekly cisplatinum and metronomic dosing of cyclophosphamide and methotrexate in second line metastatic breast cancer triple negative, EurJ Cancer, 7 Leone, 2009, Neoadjuvant platinum-based chemotherapy for triple-negative locally advanced breast cancer: Retrospective analysis of 125 patients, J Clin Oncol, 27, 15s, 10.1200/jco.2009.27.15_suppl.625 Torrisi, 2008, Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel, Cancer Chemother Pharmacol, 62, 667, 10.1007/s00280-007-0652-z Sikov, 2007, Preliminary recurrence and survival analysis of patients (pts) receiving neoadjuvant q4week carboplatin and weekly paclitaxel + weekly trastuzumab in resectable and locally advanced breast cancer: update of BrUOG BR-95, Breast Cancer Res Treat, 106, Is Frasci, 2009, Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer, Ann Oncol, 20, 1185, 10.1093/annonc/mdn748 Sirohi, 2008, Platinum-based chemotherapy in triple-negative breast cancer, Ann Oncol, 19, 1847, 10.1093/annonc/mdn395 O'Shaughnessy, 2011, Iniparib plus chemotherapy in metastatic triple-negative breast cancer, N EnglJ Med, 364, 205, 10.1056/NEJMoa1011418 O'Shaughnessy, 2007, Preliminary results of a randomized phase II study of weekly ironotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer, Breast Cancer Res Treat, 106, ls Chia, 2007, Triple-negative metastatic/recurrent breast cancer: Treatment with paclitaxel/carboplatin combination chemotherapy, J Clin Oncol, 25, 18s, 10.1200/jco.2007.25.18_suppl.1086 Uhm, 2009, Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy, IntJ Cancer, 124, 1457, 10.1002/ijc.24090 Carey, 2008, TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metasatic triple-negative (basal-like) breast cancer, Clin Oncol, 26 De Laurentiis, 2008, Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.;, Clin Oncol, 26, 44, 10.1200/JCO.2007.11.3787 Rakha, 2007, Prognostic markers in triple-negative breast cancer, Cancer, 109, 25, 10.1002/cncr.22381 Bonnefoi, 2010, Phase III trial (EORTC 10994/BIG 00-01) assessing the value of p53 using a functional assay to predict sensitivity to a taxane versus nontaxane primary chemotherapy in breast cancer: Final analysis, Clin Oncol, 28, 18s Jacquemier, 2006, Identification of a basal-like subtype and comparative effect of epirubicin-based chemotherapy and sequential epirubicin followed by docetaxel chemotherapy in the PACS 01 breast cancer trial: 33 markers studied on tissue-microarrays (TMA).;, Clin Oncol, 24, 18s Martin, 2010, Adjuvant docetaxel for high-risk, node-negative breast cancer, N EnglJ Med, 363, 2200, 10.1056/NEJMoa0910320 Roche, 2010, Five-year analysis of the FNCLCC-PACS04 Trial: FEC100 vs. ED75 for the adjuvant treatment of node positive breast cancer, Cancer Res, 69, 24s Colleoni, 2002, Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels, Ann Oncol, 13, 73, 10.1093/annonc/mdf013 Ellis, 2006, Clin Oncol, 24, 18s, 10.1200/JCO.2006.06.1143 Falo, 2007, HER-2/neu status and response to CMF: retrospective study in a series of operable breast cancer treated with primary CMF chemotherapy.;, Cancer Res Clin Oncol, 133, 423, 10.1007/s00432-006-0176-7 Colleoni, 2010, Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.;, Clin Oncol, 28, 2966, 10.1200/JCO.2009.25.9549 Perou, 2000, Molecular portraits of human breast tumours, Nature, 406, 747, 10.1038/35021093 Cuzick, 2009, Prognostic value of a combined ER, PgR Ki67, HER2 Immunohistochemical (IHC4) score and comparison with the GHI recurrence score – results from TransATAC, Cancer Res, 69, 24s, 10.1158/0008-5472.SABCS-09-74 Knoop, 2005, Retrospective analysis of topoisomerase Ha amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil, J Clin Oncol, 23, 7483, 10.1200/JCO.2005.11.007 O'Malley, 2009, Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy, J Natl Cancer Inst, 101, 644, 10.1093/jnci/djp067 Bartlett, 2010, Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601), Lancet Oncol, 11, 266, 10.1016/S1470-2045(10)70006-1 Desmedt, 2009, Predicting the efficacy of anthracyclines in breast cancer (BC) patients: Results of the neoadjuvant TOP trial J C/in, Oncol, 27, 15s Tan, 2008, Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients, Breast Cancer Res Treat, 111, 27, 10.1007/s10549-007-9756-8 Mo, 1997, Heterogeneus expression of DNA topoisomerase II alpha isoforms in tumor cell lines, Oncol Res, 9, 193 Camp, 2002, Automated subcellular localization and quantification of protein expression in tissue microarrays, Nat Med, 8, 1323, 10.1038/nm791 Collins, 2008, The comet assay: topical issues, Mutagenesis, 23, 143, 10.1093/mutage/gem051 Langie, 2006, Development and validation of a modified comet assay to phenotipically assess nucleotide excision repair, Mutagenesis, 21, 153, 10.1093/mutage/gel013 Galardi, 2009, Evaluation of DNA damages by alkaline comet assay in early breast cancer patients, Ann Oncol, 20, viii47 Graeser, 2010, A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer, Clin Cancer Res, 16, 6159, 10.1158/1078-0432.CCR-10-1027 Asakawa, 2010, Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins, Breast Cancer Res, 12, R17, 10.1186/bcr2486 Rodriguez, 2010, DNA repair signature is associated with anthracycline response in triple negative breast cancer patients, Breast Cancer Res Treat, 123, 189, 10.1007/s10549-010-0983-z